Immune responses induced in HHD mice by multiepitope HIV vaccine based on cryptic epitope modification

Molecular Biology Reports

Volumn 40, Issue 4, 2013, Pages 2781-2787

  Li, Yinghui ^a   Huang, Yuxiao ^a   Liang, Jiao ^a   Xu, Zhikai ^a   Shen, Yan ^a   Zhang, Ning ^a   Liu, Zhongxiang ^a   Zhao, Ya ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cryptic epitope; HIV vaccine; Immune responses; Multiepitope

Indexed keywords

ANTIGEN P24; BINDING PROTEIN; DNA VACCINE; EPITOPE; GAG PROTEIN; HLA A2.1 BINDING PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PEPTIDE VACCINE; POL PROTEIN; PROTEIN VARIANT; TYROSINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; BIOINFORMATICS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE CONSTRUCT; HHD MOUSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOTHERAPY; IN VIVO STUDY; MOUSE; MOUSE STRAIN; MULTI CTL EPITOPE GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PROTEIN BINDING; VACCINE PRODUCTION; VIRUS GENE; VIRUS MUTATION;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; GENES, POL; HIV; HIV INFECTIONS; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, ACTIVE; MICE;

MUS;

EID: 84878401630     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2202-y     Document Type: Article

References (20)

1. Goulder PJ, Rowland-Jones SL, McMichael AJ, Walker BD (1999) Anti-HIV cellular immunity: recent advances towards vaccine design. AIDS 13(Suppl A):S121-S136
2. Schmitz JE, Simon MA, Kuroda MJ, Lifton MA, Ollert MW, Vogel CW et al (1999) A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am J Pathol 154:1923-1932
3. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P et al (2000) A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 30:3411-3421
4. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A et al (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425-433
5. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D et al (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750-1758
6. Huarte E, Sarobe P, Lu J, Casares N, Lasarte JJ, Dotor J et al (2002) Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clin Cancer Res 8:2336-2344
7. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O et al (2002) HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900-5906
8. Newberg MH, Smith DH, Haertel SB, Vining DR, Lacy E, Engelhard VH (1996) Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol 156:2473-2480
9. Sarobe P, Pendleton CD, Akatsuka T, Lau D, Engelhard VH, Feinstone SM et al (1998) Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest 102:1239-1248
10. Firat H, Tourdot S, Ureta-Vidal A, Scardino A, Suhrbier A, Buseyne F et al (2001) Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur J Immunol 31:3064-3074
11. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Pérarnau B (1997) HLA-A2.1-restricted education and cytolytic activity of CD8+ T lymphocytes from β2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Db β2m double knockout mice. J Exp Med 185:2043-2051
12. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA et al (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3:212-217
13. Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP et al (1995) Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 181:1365-1372
14. Virgin HW, Walker BD (2010) Immunology and the elusive AIDS vaccine. Nature 464:224-231
15. Deck RR, DeWitt CM, Donnelly JJ, Liu MA, Ulmer JB (1997) Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine 15:71-78
16. Robinson HL, Boyle CA, Feltquate DM, Morin MJ, Santoro JC, Webster RG (1997) DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J Infect Dis 176(Suppl 1):S50-S55
17. Hewer R, Meyer D (2005) Peptide immunogens designed to enhance immune responses against human immunodeficiency virus (HIV) mutant strains: a plausible means of preventing viral persistence. J Theor Biol 233:85-90
18. Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F et al (2007) CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 81:2440-2448
19. Excler JL, Plotkin S (1997) The prime-boost concept applied to HIV preventive vaccines. AIDS 11(Suppl A):S127-S137
20. Ramshaw IA, Ramsay AJ (2000) The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 21:163-165